Dual targeting with 212Pb/224Ra is particularly promising since most late-stage prostate cancers have skeletal involvement, and 212Pb-PSMA ligand and 224Ra represent two different targeting approaches in one radiopharmaceutical solution. This evidence concerns the gene FOLH1 and Familial prostate cancer.